Management of Hypertension in Hemodialysis Patients

Introduction to Antihypertensive Agents

The American College of Cardiology recommends choosing between dialyzable and non-dialyzable antihypertensives based on intradialytic blood pressure patterns, avoiding non-dialyzable agents in patients with frequent intradialytic hypotension, and preferring non-dialyzable agents for patients with intradialytic hypertension or stable intradialytic blood pressure 1, 2
The Kidney Disease Outcomes Quality Initiative suggests that atenolol and metoprolol are highly dialyzable and removed during hemodialysis sessions, making them preferable for patients with frequent intradialytic hypotension 1, 2, 3

For patients with frequent intradialytic hypotension, prioritize dialyzable agents such as atenolol, metoprolol, and enalapril to minimize hypotension risk during dialysis, and consider administering medications after dialysis rather than before 1, 2
For patients with intradialytic hypertension, prioritize non-dialyzable agents such as propranolol, carvedilol, and all calcium channel blockers to maintain therapeutic levels throughout dialysis 1, 2
The American Heart Association recommends using ACE inhibitors or ARBs as first-line agents for most patients, as they reduce left ventricular mass index independent of blood pressure reduction and may preserve residual kidney function 1, 2, 3

Beta-blockers are recommended as first-line agents for patients with coronary artery disease or heart failure, with the choice based on dialyzability considerations 1, 2, 3
Calcium channel blockers are associated with decreased total and cardiovascular mortality in observational studies and are a reasonable first-line choice for patients without specific cardiovascular indications 3

Never initiate or escalate antihypertensive medications without first optimizing volume status through ultrafiltration and sodium restriction, as volume overload underlies most hypertension in dialysis patients 1, 2, 4
Avoid using non-dialyzable agents, especially carvedilol, in patients with recurrent intradialytic hypotension, as they maintain therapeutic levels during dialysis and increase hypotension risk 1, 2